Marchwell Ventures Ltd. and Sante Veritas Therapeutics Inc. Enter into Definitive Agreement to Complete Reverse Take-Over

Vancouver, British Columbia--(Newsfile Corp. - January 31, 2018) - Marchwell Ventures Ltd. (TSXV: MVE.H) ("Marchwell") and Santé Veritas Therapeutics Inc. ("SVT") are pleased to announce that they have entered into a definitive business combination agreement (the "Amalgamation Agreement") dated January 26, 2018 whereby Marchwell will combine with SVT to create a medical and adult use cannabis cultivation company (the "Transaction").

Santé Veritas Therapeutics Inc.

SVT is a privately-held corporation incorporated in British Columbia in 2012 for the purpose of obtaining a licence under the Access to Cannabis for Medical Purposes Regulations (the "ACMPR") and to thereafter operate as a medical cannabis cultivation company. Health Canada has recently issued SVT a "confirmation of readiness" for a licence under the ACMPR.

SVT is currently constructing its cultivation facilities in Powell River, British Columbia, on a site that was formerly a paper mill. SVT anticipates receipt of Licensed Producer status, permitting it to begin cultivation, in February 2018. On December 19, 2017, SVT completed a private placement of common shares for gross proceeds of approximately $16 million (the "Private Placement") to fund construction of its facilities.

All information provided in this press release related to SVT has been provided by management of SVT and has not been independently verified by management of Marchwell.

The Transaction

Pursuant to the terms of the Amalgamation Agreement:

  • Marchwell will consolidate (the "Consolidation") its outstanding shares on a three into one basis; and

  • Marchwell will acquire all of the issued and outstanding shares of SVT pursuant to a three-cornered amalgamation whereby 1148607 Inc. ("Marchwell Subco"), a wholly-owned subsidiary of Marchwell, and SVT will amalgamate (the "Amalgamation") to form a newly amalgamated company ("Amalco"), and upon the Amalgamation, former shareholders of SVT ("SVT Shareholders") will receive one New Marchwell Share (as defined below) for each one SVT Share held and Amalco will become a wholly-owned subsidiary of Marchwell.

There are currently 23,438,433 Marchwell common shares issued and outstanding. On closing, there will be approximately 245 million SVT common shares outstanding. As a result of the Transaction, Marchwell expects to have approximately 253 million issued and outstanding common shares on an undiluted basis. Approximately 3% of those shares will be held by shareholders of Marchwell and 97% will be held by former shareholders of SVT. The shares held by new "principals" of Marchwell will be subject to such escrow requirements as may be imposed by the securities regulatory authorities.